SCHEMBL5876485

SCHEMBL5876485

Cc1ccc(S(=O)(=O)n2nc(N)c3c2CC(c2ccccc2)(c2cccc(N(C)C)c2)C=C3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.36
ALDH1A1 P00352 5/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 6/20 0.34
MEN1 O00255 3/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
NPY5R Q15761 1/20 0.33
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
F2 P00734 1/20 0.32
CTSB P07858 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GAA P10253 2/20 0.32
CXCL8 P10145 1/20 0.32
NOD2 Q9HC29 1/20 0.32
NOD1 Q9Y239 1/20 0.32
CA12 O43570 1/20 0.32
CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5877763 0.97 MAPT (0.38) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL5876602 0.92 MAPT (0.41) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL5875992 0.90 ALDH1A1 (0.41) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL5876036 0.88 KMT2A (0.42) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL5876744 0.88 KMT2A (0.38) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL5876799 0.88 ALDH1A1 (0.36) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5876345 0.86 MAPT (0.33) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL5877202 0.86 MAPT (0.35) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5877152 0.86 MAPT (0.41) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL5877311 0.85 MAPT (0.34) MAPTALDH1A1SMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT MAPT 1879/4885ALDH1A1 166/4885SMN1; SMN2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.